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Background: Magnetic resonance imaging (MRI) plays an important role in tumor detection/diagnosis. The use of
exogenous contrast agents (CAs) helps to improve the discrimination between lesion and neighbouring tissue, but most
of the currently available CAs are non-specific. Assessing the performance of new, selective CAs requires exhaustive assays
and large amounts of material. Accordingly, in a preliminary screening of new CAs, it is important to choose candidate
compounds with good potential for in vivo efficiency. This screening method should reproduce as close as possible the
in vivo environment. In this sense, a fast and reliable method to select the best candidate CAs for in vivo studies would
minimize time and investment cost, and would benefit the development of better CAs.
Results: The post-mortem ex vivo relative contrast enhancement (RCE) was evaluated as a method to screen
different types of CAs, including paramagnetic and superparamagnetic agents. In detail, sugar/gadolinium-loaded
gold nanoparticles (Gd-GNPs) and iron nanoparticles (SPIONs) were tested. Our results indicate that the post-mortem
ex vivo RCE of evaluated CAs, did not correlate well with their respective in vitro relaxivities. The results obtained with
different Gd-GNPs suggest that the linker length of the sugar conjugate could modulate the interactions with cellular
receptors and therefore the relaxivity value. A paramagnetic CA (GNP (E_2)), which performed best among a series
of Gd-GNPs, was evaluated both ex vivo and in vivo. The ex vivo RCE was slightly worst than gadoterate meglumine
(201.9 ± 9.3% versus 237 ± 14%, respectively), while the in vivo RCE, measured at the time-to-maximum enhancement
for both compounds, pointed to GNP E_2 being a better CA in vivo than gadoterate meglumine. This is suggested to
be related to the nanoparticule characteristics of the evaluated GNP.
Conclusion: We have developed a simple, cost-effective relatively high-throughput method for selecting CAs for
in vivo experiments. This method requires approximately 800 times less quantity of material than the amount used for
in vivo administrations.
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Figure 1 Short name: Schematic representation of the
paramagnetic Gd-chelate containing gold glyconanoparticle
(Gd-GNPs). Detailed legend: Schematic representation of the
paramagnetic Gd-chelate containing gold glyconanoparticle
(Gd-GNPs) tested in this work. The gold core (Au) is coated with
Gd:DO3A derivatives and self-assembled monolayer of saccharide
conjugates. Thiol-ended alkane linkers are used as spacers to attach the
conjugates to the gold core. Figure not drawn to scale. Glc = glucose.
See also Table 1, text and reference [7] for further details.
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Magnetic resonance imaging (MRI) plays an important role
in early tumor detection and diagnosis. The use of exogen-
ous contrast agents (CAs) [1,2] is helpful to improve the
discrimination between lesion and neighbouring tissue.
Contrast agents (CAs) can enhance tissue contrast
by shortening longitudinal (T1) and transverse (T2)
relaxation times of water. The magnitude of this effect is
measured as relaxivity (r1 or r2) and it is related to the
efficacy of the CAs in accelerating relaxation. This
parameter can be modulated by many factors, such as
protein binding, chemical structure and dynamic processes
(e.g. water exchange kinetics, first and second coordination
sphere hydration, rotational tumbling rates) [3,4]. When
administered at equivalent doses, compounds with high
relaxivity values could generate greater contrast than
compounds with lower relaxivity, and therefore less
amount is required to generate the same effect. On
the other hand, compounds with low in vitro relaxivity but
with specific binding to some cellular/molecular targets can
also have potential application as CAs in MRI [5]. Most of
the currently available extracellular CAs are non-specific
and less efficient than predicted by theory [6], and most of
the in vitro strategies used to evaluate their performance
are not able to reproduce the in vivo conditions that could
modify their ability to generate contrast [5,7-9].
Analyzing the in vivo performance of a new candidate
CA involves exhaustive assays and requires large amounts
of material, not always available at early stages of product
development. Accordingly, a preliminary screening of new
CAs should ideally choose candidates with good in vivo
potential, in order to minimize time and cost invested. In
this process, one also needs to consider the ability of the
CA to reach the target tissue and to interact with the
extracellular matrix or substances released by cells. In this
sense, the standard in vitro method currently used for
evaluating CA performance, relaxivity calculation [10],
may not be a good predictor of in vivo performance. Up
to date, there is not any “ideal” ex vivo method, although
some have been described [11,12]. The use of a fast and
reliable method to select CAs from a range of candidates,
reproducing as close as possible the biological environment
and requiring small amounts of material, would benefit the
development of new and better CAs.
The purpose of this work was to design and evaluate a
simple ex vivo method to assess the performance of new
CAs for preclinical brain tumor detection using minimal
amounts of material. This method should be a better
predictor of in vivo performance than classic in vitro
relaxivity measurements. To validate it, we have tested
novel paramagnetic Gd-based gold nanoparticles (Gd-GNPs)
(Figure 1) [7,13] as well as superparamagnetic iron oxide
nanoparticles (SPIONs) [14]. The Gd-GNPs incorporate
several copies of sugars (which confer biocompatibilityand water solubility) and Gd complexes. The multivalent
presentation of sugars in these Gd-GNPs gives them target-
ing properties, enhancing their avidity for carbohydrate-
binding receptors at the cell surface and could also
modulate their cellular uptake.
Iron oxide, and specifically iron oxide nanoparticles,
are the most investigated material for negative CA in
biomedicine because of its high magnetic moment,
chemical stability in physiological conditions and low
toxicity [15,16]. Further engineering of these nanoparticles
should improve their performance, making them more
selective and thus more efficient [17-20]. Nevertheless,
some of the modifications introduced in the iron nanopar-
ticles can alter their superparamagnetic properties
(and, hence, the contrast effect obtained) which should be
evaluated before going further in nanoparticle development.Results
Post mortem ex vivo RCE analysis and in vitro 1.4 T and
7.0 T relaxivity measurements were performed for all
nanoparticles, while in vivo measurements in mice were
restricted to the best performing Gd-GNP candidate.
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The r1 relaxivity values were measured for positive contrast
agents, both at 1.4 and 7.0 T, and are listed in Table 1. As
expected, r1 decreases with increasing magnetic field [21].
At 1.4 T, all the Gd-GNPs relaxivity values were higher
than gadoterate meglumine, whereas at 7.0 T a higher
dispersion was observed, with values both above and below
gadoterate meglumine. It should be noted that the value
obtained in vitro at 7.0 T for gadoterate meglumine (one of
the gold standards for Gd-containing CAs), is in good
agreement with literature values obtained in vivo for
Gd-DTPA at 6.3 T (3.0 mM−1 s−1) [22], although at slightly
different temperature (23°C in vitro and 37°C in vivo).
Ex vivo post mortem MRI analysis
A representative T1-weighted image for Gd-GNP (E_2),
as well as typical regions of interest (ROIs) selected for
analysis, are shown in Figure 2A and 2B. The contrast
enhancement obtained with this method clearly varies
depending on the Gd-GNP investigated (Figure 2C). All
Gd-GNPs investigated produced significantly lower
contrast enhancement compared with gadoterate meglu-
mine (236.7 ± 8.3% with respect to contralateral RCE,
Table 1). The only exception was GNP (F) which was
lower but not significantly. Among all GNPs, the GNP
(E_2) presented the highest contrast enhancement (201.9 ±
9.3%). These results could be partially explained due to
the differences in r1 and r2/r1 (Table 1) among the differ-
ent CA. All GNPs but GNP (E_2) presented r2/r1 ranging
from 5.00 to 11.06, clearly higher than the r2/r1 ratio mea-
sured for gadoterate meglumine (1.70). On the other
hand, the r2/r1 ratio for GNP (E_2) was of 1.77. In
addition, these results suggest that the sugar linker length
could play a role in the results: GNPs with a C5 linker for
sugars (GlcC5 (GNP E_1), GalC5 (GNP J)) tend to provide
higher positive contrast enhancement (%RCE), when the
chelating DO3A linker is C11 long. Still, GlcC2 (GNP F)
also produced good results.
The ex vivo post-mortem MRI method was also suc-
cessfully applied to iron-oxide nanoparticles. The results
obtained have been summarized in the supplementary
material (Section 2).
In vivo MRI analysis
T2-weighted images demonstrated the expected, predict-
able increase in tumor size and the overall morphology
of a high grade glial tumor at 10 days post-inoculation
of GL261 cells (Figure 3). The most consistent imaging
finding in these tumors is the enhancement after con-
trast administration on post-contrast T1-weighted im-
ages. In this case, both contrast agents evaluated in vivo
(gadoterate meglumine and GNP (E_2)) showed positive
contrast enhancement on T1-weighted images (Figure 3,
T1-ref vs.T1-max, and Figure 4).Following the same trend observed in the ex vivo post-
mortem studies, the GNP (E_2) showed a significantly
(p < 0.05) worse performance in GL261 tumors (RCE
107.9 ± 5.9%) in comparison with gadoterate meglumine
(113.1 ± 2.5%) when they were measured both at 2 min
56 sec post administration (corresponding to the time of
maximum enhancement of gadoterate meglumine,
Figure 4). The discrepancy between the ex vivo post-
mortem studies (Table 1) and the information depicted
in Figure 3 (RCE maps) is related to the time for max-
imum enhancement of each CA, which is significantly
longer for GNP (E_2) (about 8 min) than for gadoterate
meglumine (about 3 min) (p < 0.001), (Figure 4). If we
take into account RCE at time of maximum enhance-
ment for each CA (Figure 5), the GNP (E_2) outper-
forms gadoterate meglumine: RCE of 124.9 ± 8.3 and
113.1 ± 2.5%, respectively. In vivo imaging results were
complemented by Induced Coupled Plasma-Mass
Spectrometry (ICP-MS) measurements of gold content
in tumor and normal brain (Figure 6). Indeed, Gd-GNP
biodistribution assays after 24 h demonstrated that
mouse brain tumors administered with GNP (E-2) accu-
mulated almost ten times more CA than normal brain,
and nearly twice the amount in circulating blood.
Renal and hepatic function parameters were also mea-
sured from the blood of animals administered with
nanoparticles in vivo, including glucose, total proteins,
albumin, creatinine, urea, total bilirrubine, aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT)). Histopathological studies were also conducted,
24 h and 14 days post-administration of the CAs. No
significant changes were found in any of the blood bio-
chemical parameters analyzed in mice administered with
GNP (E_1 or E_2) compared to control mice (only
vehicle) as shown in Additional file 1: Table S1. More-
over, values for the three groups of mice remained
within reference values [23,24]. Similarly, no alterations
were found in histological sections of relevant organs
such as liver, spleen and lungs (Additional file 1: Figure S2).
Overall, these data suggest that the nanoparticles were
non toxic to the animals in the time frame investigated al-
though more detailed toxicological studies would be re-
quired in order to confirm (or refute) this assertion.
Pharmacological parameters for CA tumor perfusion
Table 2 and Figure 7 summarize % of RCE ex vivo, % of
RCE in vivo, Kep (exchange rate constant) and IAUC
(initial area under the curve) for the gadoterate meglu-
mine and the GNP (E_2), which had a full evaluation
in vitro, ex vivo and in vivo.
Discussion
Gadolinium complexes are widely used as positive CA in
clinical MRI examinations. Besides the well known
Table 1 Gd-GNPs studied, percentage of Gd (in g of Gd per 100 g of nanoparticle), relaxivity values (r1, r2 and r2/r1) and relative contrast enhancement (RCE) values
Contrast agent Gd-GNP
(Glyco-Au-D03A:Gd)a
% Gd (g of Gd per 100 g
of nano particle)
1.4 T r1relaxivity
(s−1 mM−1) (in vitro) (n = 3)
7.0 T r1 relaxivity
(s 1 mM−1) (in vitro) (n = 3)
7.0 T r2 relaxivity (s
−1 mM−1)




(ex vivo) (n = 3)
% RCE (in vivo**)
(n = 3)
GlcC5-DO3AC11 (GNP (E_1)) 4.7 ± 0.1 7.4 ± 0.7 2.7 ± 0.40 20.2 ± 0.11 7.48 182.8 ± 10.7* NM
GlcC2-DO3AC11 (GNP (F)) 3.4 ± 0.2 7.1 ± 0.9 2.9 ± 0.04 14.5 ± 2.37 5.00 185.4 ± 17.2 NM
GlcC9-DO3AC11 (GNP (G)) 3.2 ± 0.2 7.5 ± 0.6 1.6 ± 0.15 12.7 ± 0.24 7.94 168.7 ± 7.74* NM
GlcC7-DO3AC11 (GNP (H)) 4.1 ± 0.2 7.1 ± 0.9 1.6 ± 0.36 11.2 ± 0.21 7.00 143.6 ± 8.0* NM
GlcC3-DO3AC11 (GNP (I)) 3.3 ± 0.2 6.3 ± 0.7 1.8 ± 0.07 19.9 ± 1.43 11.06 141.5 ± 2.5 NM
GlcC5-DO3AC11 (GNP (E_2))b 7.0 ± 0.2 11.5 ± 0.1 8.2 ± 0.37 14.5 ± 0.66 1.77 201.9 ± 9.3* 124.9 ± 8.3*
GlcC5-DO3AC11 (GNP (J)) 5.0 ± 0.2 8.1 ± 0.3 4.6 ± 0.24 24.4 ± 0.34 5.30 169.1 ± 14.1* NM
Gadoterate meglumine NA 3.10c/3.5d 2.1 ± 0.42 3.58 ± 0.02 1.70 236.7 ± 8.3 113. 1 ± 2.5
Detailed legend:
a)Glc = glucose, Gal = galactose. C (number) after the saccharide and the DO3A indicates the number of carbon atoms of the linkers.
b) GNP (E_2) was obtained from GNP (E_1) after further incubation with a solution of DO3AC11-Gd complex (4 equiv.) during 44 hours as described in [31].
c) Values taken from [7].
d) Values taken from [58].
*p < 0.05 versus gadoterate meglumine.
**Mean of RCE values (n = 9 independent measures for 3 animals) measured at the maximum enhancement time, for each of the CA studied in vivo.
NM, not measured. NA, not applicable.

















Figure 2 Short name: Ex vivo MRI and example of Gd-GNPs evaluated; Boxplot of relative contrast enhancement. Detailed legend:
A) Representative ex vivo T1-weighted image and example of ROIs used (manually drawn as circles, green (ipsilateral) and yellow (contralateral) lines)
for signal enhancement calculation for GNP (E_2). B) Enlarged central row (white discontinuous rectangle) C) Boxplot of relative contrast enhancement
for saline solution, gadoterate meglumine (G.M.) and GNPs obtained from ROIs of all CAs studied. RCE was calculated using Equation 1. The limits of
the box represent the quartiles 1 (Q1) and 3 (Q3) of the distribution, the central line corresponds to the median (quartile 2) and the whiskers represent
the maximum and minimum value in each distribution. The data represented were included in the range [Q1-1.5 IQR - Q3 + 1.5 IQR], being IQR the
interquartile range.
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fibrosis [25], they are non specific, i.e. able to detect
anatomical and morphological changes but not a specific
pathology. Developing contrast agents with specific
targeting properties would have a significant clinical
impact. One of the ways to approach this goal is toFigure 3 Short name: Coronal T2-weighted images, DCE-MRI images a
legend: From left to right, representative coronal T2-weighted images, DCE
maximum contrast enhancement point (T1-max)), and RCE maps of two m
meglumine (top), and the other with GNP (E_2) (bottom). T1-ref images we
images correspond to the point of maximum contrast enhancement after ga
bars on top of RCE provide intensity range shown in figures. Black pixels corre
RCE postprocessing limits as described in methods.develop nano-platforms for attaching simultaneously a
CA and targeting molecules forming nano-sized contrast
agents [26-30].
The new positive CAs tested in this work are gold
glyconanoparticles (GNPs) coated with multiple copies
of sugars and Gd-complexes (Gd-GNPs) (Figure 1nd RCE maps of two mice bearing a GL261 glioma. Detailed
-MRI images (T1-weighted reference prior to contrast (T1-ref) and at the
ice bearing a GL261 glioma. One animal was studied with gadoterate
re acquired before injecting the contrast agent bolus while T1-max
doterate meglumine or GNP administration (see Figure 4). Colour coded
spond to instances with values above or below the user-established %
Figure 4 Short name: RCE time-course curves obtained from the quantification of DCE-MRI images. Detailed legend: RCE time-course
curves obtained from the quantification of DCE-MRI images. Each curve displays the average contrast enhancement obtained for each group of
mice. Values correspond to the results obtained from 3 animals/group and 3 slices/animal, i.e. n = 9 measurements/group. Gadoterate meglumine,
open symbols; GNP (E_2), filled symbols. Tumor is coded by circles and contralateral non-tumoral areas by triangles. Bars show +/−SD.
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to target mouse brain tumors [7,31] mimicking the multiva-
lent presentation of carbohydrates at the cell surfaces
[32,33]. These GNPs represent a novel multivalent platform
for biological applications [29,34-37], soluble and stable
under physiological conditions, and resistant to enzymatic
degradation [38]. We selected simple carbohydrates to coatFigure 5 Short name: Boxplot of %RCE obtained both ex vivo
and in vivo at the T1-max time. Detailed legend: Boxplot for
comparison of %RCE obtained both ex vivo (red boxes) and in vivo
(green boxes, at the T1-max time for each CA being studied) for
gadoterate meglumine and GNP (E_2).the Gd-based gold nanoparticles, as they are important
nutrients for cells. Also, their uptake/binding is dependent
on the expression of specific transporters (i.e. GLUTs) [39],
and carbohydrate-binding proteins (lectins) which may
confer targeting properties to the Gd-GNPs.
Different approaches have been tested to improve
the assessment of new CAs, such as: studies with
tumor-bearing animals, with no intermediate steps de-
scribed between the CA evaluation in vitro and in vivo as-
says [40], computational simulation methods to predict
the behaviour of a conditional CA [8], incubation of a CA
with a gliosarcoma cell line in well plates to check
for interaction and internalization using MRI [41], or
incubation of a targeted CA with a cell line over-expressing
the folate receptor in order to evaluate the efficiency
of the targeting [42]. Those approaches based on in vitro
relaxometry measurements incorporating the use of cell
lines, are useful for high throughput CA analysis, but do
not fully reproduce the in vivo environment [41]. In this
respect, the interaction of the CA with extracellular
macromolecules or proteins, may restrict the overall chelate
mobility, and thus change its relaxivity [3]. Additionally,
post mortem ex vivo approaches have been previously used
to approximate the CA performance potential in vivo
[11,12]. Those ex vivo studies [11,12] were conceptually
similar to our herewith described method. Nonetheless, the
tissues investigated by them (mouse leg [11] or subconjunc-
tive eye tissue [12]), were not classical tissues for contrast
enhancement experiments, as done in our case (brain/brain
tumor). Authors in [11] did not proceed into comparing
the performance of different CA or validated the possible
Figure 6 Short name: Gold (Au) biodistribution as measured by ICP-MS 24 h post-administration of GNP (E_2). Detailed legend: Gold (Au)
biodistribution as measured by ICP-MS 24 h post-administration of GNP (E_2). Inset shows tumor Au accumulation at a different scale, compared to
element concentrations in plasma and contralateral brain. The difference of Au accumulation between contralateral brain and tumor is nearly signifi-
cant for GNP (E-2), p =0.056. Values are shown as mean parts per million (ppm) and SD (bar). Statistical comparisons correspond to unpaired t-tests.
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[12] did compare ex vivo post-mortem data with in vivo
data, but the emphasis was placed in CA clearance rate
changes between low and high molecular weight CA
rather than in the development and evaluation of a
method to gauge contrast potential among different
agents. Generally speaking, several effects related to the
in vivo environment cannot be easily evaluated in vitro.
Accordingly, we believe that this biological environment
should be mimicked as closely as possible in order to
achieve an optimal prediction of the CA potential. In this
sense, our method should perform better than previously
described strategies [8,11,12,38-40]. The results obtained
in this study, which will be discussed next, suggest the
importance of taking into account not only these CA
in vivo environment effects because other factors, such as
Gd loading and macromolecular behaviour of the CA,
could also play a role and should be considered as relevant.
Effect of nanoparticle coating in positive CA results
We have previously observed that small modifications in
the chemical structure of ligands coating the Gd-GNPsTable 2 RCE ex vivo, RCE in vivo, Kep and IAUC values obtaine
CA % Ex vivo RCE % In vivo RCE at T1-m
Gadoterate meglumine 236.7 ± 14.4 113.1 ± 2.5
GNP (E_2) 201.9 ± 16.1 124.9 ± 8.3*
Detailed legend:
% RCE in vivo is shown both at T1-max of each CA and at 3 min after their administ
* p < 0.05 in comparison with gadoterate meglumine.lead to changes in its contrast enhancement effects [7].
This could be due to the Gd hydration number or the
overall CA correlation time which, in turn, could affect
their relaxivity.
When considering the in vitro relaxivity measurements
described in this work, differences (see Table 1) were
observed among the GlcCX-DO3AC11 series (GNPs
(E_1), (E_2) and F-J, X being a number between 2 and 9).
These differences could be influenced by the length
of the saccharide’s linker, which could modulate the
access of water to the Gd chelated ion. As an example,
GlcC3-DO3AC11 (GNP I) has the lowest r1 value at 1.4 T
(for glucose GNPs) and tends to be in the low range values
region at 7.0 T. On the other hand, there was a tendency to
obtain better r1 values at 1.4 T with C5 linkers (e.g. GNPs
(E_2) and J) and the same tendency is observed at 7.0 T,
despite a slightly different behaviour is seen in GNP (E_1).
The ex vivo post mortem studies showed discrepant
results compared to in vitro r1 values: the GlcC5 linker
did not produce a high RCE, as expected from the
in vitro r1 results. In this sense, the in vitro high relaxivity
values measured for the GNPs (E_2) and (J) did not turnd with in vivo studies
ax % In vivo RCE at 3 min Kep (min
−1) IAUC (A.U.)
113.1 ± 2.5 0.32 ± 0.36 2.8 ± 0.1
107.9 ± 2.0* 0.06 ± 0.03* 2.6 ± 0.2*
ration.
Figure 7 Short name: Coronal in vivo T1-weighted MRI of mice
bearing GL261 gliomas, with superimposed Kep colour-coded
maps. Detailed legend: A) Representative coronal in vivo T1-weighted
images, with superimposed Kep colour-coded maps of two mice bearing
a GL261 glioma, administered with Gadoterate Meglumine (left), and
GNP (E_2) (right). The black pixels correspond to instances with values
above or below the user-established Kep limits (see Methods). The color
scale on top shows the range of values found for Kep in each case, as
well as their color coding. B) Boxplot for comparison of Kep (min
−1)
obtained with all in vivo studied animals, using the same contrast agents
shown in A). Significant differences (p < 0.05) are marked with a triangle.
The limits of the box represent the quartiles 1 (Q1) and 3 (Q3) of the
distribution, the central line corresponds to the median (quartile 2) and
the whiskers represent the maximum and minimum value in each
distribution. The data represented were included in the range
[Q1-1.5 IQR - Q3 + 1.5 IQR], being IQR the interquartile range. Outliers
are represented outside the whiskers in two ways: as a circle if its
value is in the range [Q1-1.5 IQR > value > Q1- 3.0 IQR or Q3 + 1.5
IQR < value < Q1- 3.0 IQR], or as an asterisk if values are above or below
this threshold.
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that the Gd loading (between 3.2 and 7% Gd in weight of
nanoparticle, see Table 1 for details) of these GNPs, could
have an influence in the RCE obtained in each case, even
if correcting the preparation of the CAs solutions toachieve the same final concentration of Gd for ex vivo
post mortem studies. In this respect, the percentage Gd
content per nanoparticle significantly correlates with r1,
but not r2 (Additional file 1: Figure S1). Thus the benefi-
cial effect of high payload per nanoparticle has been dem-
onstrated for positive contrast targeted nanoparticles in
ex vivo studies with cultured cells [43]. This fact could also
explain the differences between GNPs (E_1) and (E_2),
which have the same structural formula but different
percentage of Gd (per mass of GNP), and different r1
values in vitro as well as different RCE ex vivo. Moreover,
the nature of the carbohydrate may play a role in the
ex vivo post-mortem RCE. This could be observed for
GNP (J), coated with galactose, where the high r1 values at
1.4 T and 7.0 T did not turn into high RCE ex vivo. It is
also worth pointing out the possible r2 contribution
which could counteract the r1 effect [44], and, therefore,
the overall RCE (e.g. GNP (E_1), r2/r1 = 7.48 and %RCE =
182.8; GNP (E_2), r2/r1 = 1.77 and %RCE = 201.9, see
Table 1 for further details).
Additionally, the length of the alkane linkers for glucose
may modulate the interactions with the cellular receptors,
and, accordingly the targeting of the investigated nanoparti-
cles. It is well known that GLUT-1 transporters for glucose
are overexpressed in tumor cells [45] and its structure has
been extensively investigated. In this respect, an “optimal”
length of the saccharyde linker in the CA glucose
series may be required to properly interact with the
GLUT-1 transporters, which would translate into
maximum restriction of the Gd3+ chelate mobility and
low correlation times. The length of the alkane linker
may modulate these interactions. In this sense, the
“C3-linker” (GNP I) produced one of the lowest ex vivo
RCE values measured in the GlcCX-DOTAC11 series. We
also found significant differences compared to C5 and C9
linkers (GNP (E_1) and GNP (G)). This would suggest that
a glucose linker arm too short could compromise proper
interaction of the GNP with GLUT transporters, although
additional studies will be needed to fully evaluate this possi-
bility. Furthermore, results in [46] provide some support to
the “targeting” hypothesis by showing that glucose-coated
niosomes produced contrast-enhancement, whereas
niosomes without glucose produced no enhancement,
reinforcing the possibility that this interaction nanoparticle-
transporter is also present in our case. Besides to possibly
modulating ex vivo/in vivo CA relaxivity values, the
use of glucose could also help targeting the CA-containing
nanoparticles to tumor cells by means of their glucose
transporters.
Preliminary results comparing the in vivo effects of a
similar GNP (with the same structural formula as GNP
E_1 and E_2) in the same tumor model did not show
significant differences in the maximum RCE changes
observed during different glycemic states, euglycemia
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shown). This suggests that the possible competition
between the glucose GNPs and free glucose for the inter-
action with GLUT transporters does not seem to
affect their performance as T1 contrast agents. None-
theless, further assays on the in vivo competition between
glucose GNPs with and without chelated Gd should help
to clarify the point about the contribution of the glucose
GNP binding to GLUTs in the measured RCE.
The in vitro r1 relaxivity value for GNP (E_2) at 7 T
was the best among the Gd-GNPs (Table 1), but the ex vivo
analysis did suggest slightly, but significant, worse
performance than gadoterate meglumine. The ex vivo
and in vivo RCE measurements both predicted worse
performance of GNP (E_2) compared to gadoterate
meglumine when RCE was measured at the same time
point (3 min post CA injection, time of maximum
contrast enhancement for gadoterate meglumine) (Table 2).
However, when RCE was measured at the time of
maximum enhancement for each CA in the DCE-MRI
experiments, the GNP (E_2) performed significantly
better than gadoterate meglumine (see Table 2 and
Figure 5). Significant differences were found in the
maximum time of contrast enhancement (“T1-max”)
between the two analyzed CA, and this points to the
fact that the behaviour of GNP (E_2) is the expected one
for a macromolecular-like contrast agent [12]. This may
be due to the well known “enhanced retention” (EPR)
effect of nanoparticulated CAs in tumors [47]. The
described diameter of the GNPs is between 1.8-4.5 nm [7],
comparable to agents used as macromolecular contrast
agents (4–6 nm, [12,48]), and therefore reach the
time to maximum enhancement more slowly than free
gadolinium chelate (gadoterate meglumine) (Figure 4).
This result agrees with previous results obtained using
niosomes by authors in [46] although with a different
tumor type. Finally, the gold biodistribution found in our
study (e.g. maximal accumulation found in liver and
spleen, Figure 6) is in good agreement with literature for
gold nanoparticles [49,50].
The pharmacological parameters measured for gadoterate
meglumine and GNP (E_2) (e.g. Kep, see Figure 7 and
Table 2) were significantly different. Authors in [12] have
previously shown that CAs with different molecular sizes
also have different clearance rates (lower Kep values), which
becomes slower with higher molecular weight CAs.
Authors in [48] have measured a closely related parameter,
the “transfer coefficient” (KPS) (transfer rate of the
contrast agent from the blood to the interstitial space,
highly dependent on the permeability), and found an
inverse relationship between the molecular weight of
the CA and the transfer coefficient. Then, GNP (E_2)
behaves as a macromolecular contrast agent, according to
their average Kep values.Finally, in addition to the more accurate simulation of
the in vivo conditions, the ex vivo post mortem method
described here consumes a very small amount of CA
compared to an in vivo study: 800 times less in the
case of positive contrast agents (5 nmol/animal vs.
4,000 nmol/animal) and it is applicable both to positive
and negative (Supplementary Material and [51]) CA.
Furthermore, as it is carried out with sacrificed animals,
no preliminary toxicological assays are required. It is
worth pointing out that, although this method is better at
simulating the in vivo conditions, the use of animals is
costly and it would require certain facilities and compli-
ance of legal/ethical aspects, depending on the country
were researchers are based. The development of new and
improved in vitro strategies, able to evaluate cells exposing
groups or proteins able to be targeted, could also offer an
intermediate and useful step in this field.
Conclusions
In summary, we have developed a low-consumption ex vivo
method for testing the potential in vivo performance of
new contrast agents. This should allow us to choose from a
series of new candidate CAs the one/s more likely to
perform better in vivo. This method requires small
amounts of CA (e.g. 5 nmol/animal) and should allow a
more rationally informed selection, avoiding unnecessary
in vivo and toxicology tests for the ex vivo poorly perform-
ing substances. This reduces animal needs, material and
overall costs. Nevertheless, caution should be taken when
evaluating CAs with different kinetic behaviour (e.g. small
vs. high molecular weight CAs). In this case, the ex vivo
method could produce an underestimation of the actual
contrast enhancement potential. Further studies may be
needed in order to fully optimize the currently described
protocol.
Methods
Synthesis of contrast agents
Gd-complexes containing glyconanoparticles (Gd-GNP)
The positive contrast agents (Gd-GNPs) evaluated in this
work were 1.8-4.5 nm sized gold nanoparticles coated
with multiple copies of sugar conjugates and 1, 4, 7,
10-tetraazacyclododecane-1, 4, 7-triacetic acid (DO3A)
Gd-complexes. The basic structures and gadolinium
content of each Gd-GNP type are schematized in Figure 1
and listed in Table 1. The Gd-GNPs were prepared by
ligand place exchange reaction (LPE) starting from
glyconanoparticles (GNPs) coated only with sugars as
described in [13,31] (Gd-GNPs E_1, E_2 and F-J). The
sugars (glucose, galactose) are conjugated to an aliphatic
chain of variable number of carbon atoms (C2, C3, C5,
C7, C9, C11), while the DO3A derivatives contain a C11
aliphatic chain (Table 1). The obtained Gd-GNPs
were characterized by TEM, UV–vis, IR, 17O NMR
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diameter of the gold core was 1.5-2.5 nm and the number
of sugars and Gd chelates on the surface ranged between
70–130 molecules for sugars and 14–34 for Gd chelates.
The amount of Gd (III) was between 3.2% and 7.0%, deter-
mined by ICP-AES (induced coupling plasma-absorption
spectroscopy).
In vitro relaxivity studies
Studies at 1.4 T
The longitudinal T1 relaxation times of Gd-GNPs
were determined at 10, 5, 2.5, 1.25, 0.625 mg mL−1
concentrations of Gd-GNPs in water (Gd concentration
ranged from 0 to 3 mM) at 60 MHz (1.41 T) and 37°C in a
Bruker Minispec MQ-60 NMR spectrometer (Bruker
Optik, Ettlingen, Germany) at CICbiomaGUNE, San
Sebastián, Spain. The values of T1 were determined using
the inversion-recovery method. The calculation of the T1
was carried out using monoexponential fitting. Three
independent measurements of T1 were performed in
every sample for statistical analysis purposes.
Relaxivities r1 and r2 were obtained from the slopes of
the curves 1/T1 and 1/T2 vs the concentration of Gd
expressed in mM.
Studies at 7.0 T
Four different solutions ranging from 0.125 to 1 mM
in gadolinium of Gd-GNPs and gadoterate meglumine
in saline solution (NaCl 0.9%, B.Braun) were used. A
phantom using capillary tubes (1.5 mm internal diameter)
for GNP solutions, immobilized in plasticine was used for
MR scanning.
All 7 T studies (in vitro relaxivity, ex vivo post mortem
and in vivo) were carried out at the joint NMR facility of
the Universitat Autònoma de Barcelona and CIBER-BBN
(Cerdanyola del Vallès, Spain), using a 7 T horizontal mag-
net (BioSpec 70/30; Bruker BioSpin, Ettlingen, Germany)
equipped with actively shielded gradients (B-GA12 gradient
coil inserted into a B-GA20S gradient system). A quadrature
72 mm inner diameter volume coil was used for in vitro
studies whereas a quadrature receive surface coil, actively
decoupled from a linear volume resonator with 72 mm
inner diameter was used for in vivo and ex vivo studies. The
in vivo studies were performed at 37°C, whereas the in vitro
relaxivity and ex vivo post mortem studies were performed
at 23°C. A recirculating water-system, incorporated to the
animal bed, was used to control the temperature, measured
by a probe and was constantly monitored (SA Instruments,
Inc., New York, USA).
All studies started with acquiring fast T2-weighted
images in three orthogonal planes using a Rapid
Acquisition by Relaxation Enhancement (RARE) sequence;
Rare Factor, 8; field of view (FOV), 19.2×19.2 mm; matrix
size (MTX), 128×128 (150×150 μm/pixel); number of slices(NS), 14 (coronal), 7 (sagittal) and 5 (axial); slice thickness
(ST), 1 mm; interslice-thickness (IST), 1.1 mm; TR/TE,
2000/36 ms; number of averages (NA), 1; total acquisition
time (TAT), 24 sec.
After these initial sequences, relaxivity studies (T1 and
T2 maps) for Gd-GNPs were carried with the following
parameters:
For T1 maps acquisition, a RARE-VTR sequence was
chosen with RARE factor = 4; FOV, 7.0×3.5 cm; MTX,
512×256 (137×137 μm/pixel); NS, 1; ST, 1 mm; TEeff,
30 ms; TRs were according to the following list: 75, 150,
300, 600, 1200, 2400 and 4800 ms; NA, 2; TAT, 20 min.
For T2 maps acquisition, a Multi-Slice-Multi-Echo
(MSME) sequence was used; FOV, 7.0×3.5 cm; MTX,
512×256 (137×137 μm/pixel); NS, 1; ST, 1 mm; TR,
4800 ms; TEs were according to the following list: 20,
40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260,
280, 300, 320, 340, 360, 380 and 400 ms; NA, 4; TAT,
1 h 16 min.
Animal models
The animal model used for these studies was C57BL/6
healthy female control mice of 20–25 g weight. All
C57BL/6 animals were obtained from Charles River
Labs (France) and housed at the Animal Facility of the
Universitat Autònoma of Barcelona.
For the ex vivo post mortem studies n = 8 (one for each
CA) were used for the CA characterization procedures.
For the in vivo study, n = 6 mice harbouring a GL261 glio-
blastoma were used. For the orthotopic model generation,
the GL261 mouse glioma cell line was obtained from the
Tumour Bank Repository at the National Cancer Institute,
Frederick, MD, USA. Cells were grown in RPMI-1640 cul-
ture medium supplemented with 2.0 g/L sodium bicarbon-
ate, 0.285 g/L L-glutamine, 10% foetal bovine serum and
1% penicillin-streptomycin solution. Culture medium and
chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise indicated. Culture plastic was
obtained from Nunc (Roskilde, Denmark).
Tumors were induced in the six mice by intracranial
stereotactic injection of GL261 cells into the caudate
nucleus, essentially as described in [52]. MRI studies were
performed approximately 2 weeks after cell inoculation.
All studies were carried out according to protocols
approved by the local/institutional ethics committee,
according to the regional and state legislation (CEEAH
1178 and 1176).
Ex vivo and in vivo MRI studies
These studies were carried out at the joint NMR
facility of the Universitat Autònoma de Barcelona and
CIBER-BBN (Cerdanyola del Vallès, Spain), using a
7 T horizontal magnet.
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images which were acquired from three horizontal
sections of the brain in order to have a good morphological
characterization of the investigated tissue. The sequence
used for this purpose was RARE with the following parame-
ters: RARE factor = 8, FOV, 17.6×17.6 mm; MTX, 256×256
(69×69 μm/pixel); ST, 1 mm; NS, 3; TR/TE, 3000/36 ms;
NA, 4; TAT, 4 min 48 sec.
Ex vivo post mortem studies
The CAs to be used for post mortem ex vivo evaluation
were dissolved in saline solution (0.9% NaCl, B.Braun)
taking into account the estimation of Gd content previously
determined (see Table 1), in order to achieve solutions of
comparable concentrations of the desired metal. The
amount finally used for each animal was 5 nmol of Gd
dissolved in 4 μl of saline solution. A commercial solution
of Gd CA (Gadoterate Meglumine, DOTAREM®, Guerbet,
Roissy, France) was used as a standard to compare the
enhancement obtained by MRI with the GNPs.
A T1-weighted image acquisition was performed using
the same coronal sections described previously in “in vitro
7 T studies”. For this, a MSME sequence was used with:
FOV 17.6×17.6 mm; MTX, 128×128 matrix (138×138 μm/
pixel); TR/TE, 350/8.5 ms; NA, 1; number of repetitions
(NR), 15; TAT, 11 min. Animals were anesthetized and
handled as described for “in vivo studies”. After that, ani-
mals were sacrificed with an overdose of intraperitoneal
sodium pentobarbital (200 mg/kg) (Vetoquinol, Madrid,
Spain), and then immobilized on a stereotactic holder
(Kopf Instruments, Tujunga, CA, USA). The contrast
administration was carried out as described for tumor
generation [52], except that the cell suspension was
replaced with the contrast agent solution to be evaluated,
and 3 injection points at each side were administered, as
follows: 1.0 mm holes were made lateral (right) to the
midline, 2.32/2.32/2.00 mm, and with the following “Y”
coordinates along the midline: 0.10/1.5/4.5 mm. The
whole process of CA injection ex vivo took 15 minutes.
After this, the T1 weighted image acquisition was repeated
as above.
In vivo studies
Anesthesia was performed with isoflurane (B.Braun,
Melsungen, Germany) at 0.5-1.5% in O2, maintaining the
respiratory frequency between 40–60 breaths/min. Body
temperature was maintained between 36.5-37.5°C with a
recirculating water system incorporated in the animal
bed, and measured with a rectal probe. Respiration
rate and temperature were constantly monitored (SA
Instruments, Inc., New York, USA). Before immobilization
in the animal holder, each mouse was cannulated in the tail
vein using a home-built multi-delivery polyethylene tubing
system. In this case, a 30G 2-way catheter was connected,through polyethylene tubing, to 2 independent 1 mL
syringes (Becton-Dickinson S.A., Madrid, Spain) loaded
with heparinized-saline (40 U/ml) (0.9% NaCl, B.Braun and
heparin, Mayne Pharma España, Madrid, Spain) and one
contrast agent (9.7 mM in Gd). The contrast agent was
injected into the mice as a bolus (72–84 μL, about
0.04 mmol/kg) during Dynamic Contrast Enhanced
(DCE)-T1 MRI studies. Three glioma-bearing mice were
injected with gadoterate meglumine and another three
were injected with GNP (E_2) (see Results).
A DCE T1 study was then performed using three coronal
sections. For this, a MSME sequence was used with: MTX,
128×128 matrix (138×138 μm/pixel); TR/TE, 200/8.5 ms;
ST, 1 mm; NA, 2; NR, 41; TAT, 35 min. The contrast bolus
was administered after the third repetition of the complete
T1-weighted sequence (about 2.5 min after the start of the
image acquisition protocol).
Biodistribution of Gd-GNP by ICP-MS
At established time-points (24 h, 48 h, see further details
in the Additional file 1: Table S1) after GNP or vehicle
administration, animals (n = 3 for each time point) were
euthanized by cervical dislocation and required tissues
(liver, kidney, spleen, brain and tumor among others) as
well as urine and blood samples were collected and stored
at -80°C. Samples were analyzed by Induced Coupled
Plasma-Mass Spectrometry (ICP-MS) at the Unidad de
Análisis Elemental of the Scientific Technical Facilities of
the University of Barcelona.
Histopathological analysis
At established time-points (24 h, 48 h and 14 days) after
GNP or vehicle administration administration, animals
(n = 3-6 for each time point) were sacrificed by cervical
dislocation. The required tissues were dissected, fixed
and stained with Haematoxilin-Eosin.
Processing and post-processing of MR data
Ex vivo post mortem studies: all processing and
post-processing of T1 -weighted images were carried
out with Bruker software Paravision (version 4.0) and
ImageJ 1.44p (National Institutes of Health, USAa).
Three regions of interest (ROIs), corresponding to the
coordinates described in the “ex vivo post-mortem studies”
section were manually defined after visual inspection both
in the area of maximum enhancement and equivalent area
of contralateral parenchyma. The relative contrast en-
hancement (RCE) - injection site ROI vs. contralateral par-
enchyma - obtained in each case was used for calculations
(see Equation 1). Only the slice with better defined
contrast-enhanced region was measured.
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“ipsilateral” region with respect to the contrast administra-
tion and that visually shows contrast enhancement,
and S (c) is the absolute signal intensity of the equivalent
contralateral region, which serves as a control and that is
defined as “100%”.
In vivo studies: DCE-MRI data were processed using a
platform for pharmacokinetic analysis recently developed
within the intramural CIBER-BBN project PROGLIO/
PROGLIO2 using IDL (ITT Visual Information Solutions,
Boulder, CO, USA) available for download at http://www.
die.upm.es/im/archives/DCEurLAB/ from the Biomedical
Images Technologies research group of the Universidad
Politécnica de Madrid (BIT-UPM) [53], and also with
additional home written scripts in IDL as described in
[54]. RCE in vivo was calculated for each pixel as the ratio
between the maximum signal enhancement and the
average intensity before bolus injection unless otherwise
indicated, and the three slices acquired were used for this
calculation. In this way, time-course curves that quantified
the average contrast enhancement inside the tumors and
in surrounding non tumor-bearing areas of the brain
parenchyma (defined from ROIs) were generated. More-
over, color-coded maps that translated the maximum
contrast enhancement at each pixel of the FOV at the time
of maximum enhancement were also generated (RCE).
Maps with the initial area under the curve (IAUC) were
generated by integration of the dynamic curves during the
first 150 seconds after contrast agent administration, as in
[55,56] but without normalization to a reference IAUC
value – a constant arterial input function was assumed.
Kep parameters (Eq. 2) were calculated according to the
“Hoffmann-Brix” model [57]:
S tð Þ





being Kel the elimination rate of the contrast agent by the
plasma. Thus, the initial slope of the kinetic curve, detected
at short times after injection, is proportional to A.Kep,
being A the initial upslope of the enhancement curve.
For each animal and slice, ROIs were manually drawn
around the tumor. The resolution of all datasets was
reduced from 128×128 to 64×64 pixels and RCE, IAUC,
and Kep maps were generated within those ROIs. The
maps were coloured according to a scale comprising the
maximum and minimum values manually defined. Pixels
with values above or below these limits were coloured
black. The whole adjustment of each pixel (including fitting
deviation and mean errors) could be exported in an excel
format. This helped improving the accuracy of the
“Hoffmann-Brix” model, allowing us to detect inadequate
fittings which were filtered-out by defining thresholds forstandard deviation (< 0.5) and mean error (< 1.5), above
which pixels were discarded from the analysis. Statistical
analysis within the tumor regions on each slice were
carried out with SPSS 19.0 (SPSS Inc., Chicago, USA).
A total of 836 and 699 pixels were analyzed from
animals studied with gadoterate meglumine and GNP
(E_2) injection, respectively.Statistical analysis
Ex vivo post mortem studies: the overall signal change mea-
sured in T1 weighted MRI ROIs for each GNP was com-
pared with gadoterate meglumine [7,58] and saline solution.
In vivo studies: measurements from the same animal
but corresponding to different slices were considered as
independent measurements/cases (total n = 9 for each CA).
For in vivo studies, the average contrast enhancement in
the ROI inside the tumors was also compared among
animals injected with different contrast agents.
For both studies, normality was first inspected in each
group by the Kolmogorov-Smirnov test and variance
homogeneity with the Levene test. A two-tailed Student’s
t-test for independent measurements was used for statistical
analysis when data followed a normal Gaussian distribution.
If data had a non-normal distribution, Mann–Whitney U
test was used for statistical analysis. The significance level
for all tests was p < 0.05.Endnotes
ahttp://rsb.info.nih.gov/ij/.Additional file
Additional file 1: 1. Biodistribution and toxicological studies carried
out with GNP E_1 and E_2. 2. Application of the ex vivo postmortem
method to iron oxide nanoparticles.Abbreviations
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